AZ-话题@MedSci

#AZ#

260篇内容 | 4183人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714747, encodeId=17261e14747a4, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Retina：内界膜剥离的眼睛和正常眼睛中较小的中央凹无血管区（FAZ）与较厚的中央凹相关！, objectType=article, longId=107942, objectId=b2b410e94257, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2b410e94257, replyNumber=0, likeNumber=60, createdTime=2017-09-20, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2b410e94257, moduleTitle=Retina：内界膜剥离的眼睛和正常眼睛中较小的中央凹无血管区（FAZ）与较厚的中央凹相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2b410e94257)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714749, encodeId=e25c1e1474932, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=CLIN CANCER RES：AZD4547治疗晚期鳞状细胞肺癌患者, objectType=article, longId=113411, objectId=ae5911341160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae5911341160, replyNumber=0, likeNumber=65, createdTime=2018-04-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae5911341160, moduleTitle=CLIN CANCER RES：AZD4547治疗晚期鳞状细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae5911341160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714741, encodeId=30611e1474105, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=罕见病重磅消息！全球脊髓性肌萎缩症（SMA）治疗药物Spinraza获美国FDA批准, objectType=article, longId=85595, objectId=c9b38559517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9b38559517, replyNumber=0, likeNumber=68, createdTime=2017-08-28, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9b38559517, moduleTitle=罕见病重磅消息！全球脊髓性肌萎缩症（SMA）治疗药物Spinraza获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9b38559517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714743, encodeId=60201e14743ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, objectType=article, longId=93569, objectId=376693569b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376693569b4, replyNumber=0, likeNumber=81, createdTime=2018-02-10, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376693569b4, moduleTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376693569b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714745, encodeId=a9851e14745e5, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet Infect Dis：Ridinilazole与万古霉素在治疗艰难梭菌感染的比较, objectType=article, longId=97654, objectId=36cc9e654b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36cc9e654b6, replyNumber=0, likeNumber=64, createdTime=2017-11-09, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36cc9e654b6, moduleTitle=Lancet Infect Dis：Ridinilazole与万古霉素在治疗艰难梭菌感染的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36cc9e654b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714740, encodeId=01fb1e147409b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=2016NICE技术评估指南：Elbasvir–grazoprevir用于治疗慢性丙型肝炎（TA413）发布, objectType=article, longId=81113, objectId=42e58111305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42e58111305, replyNumber=0, likeNumber=28, createdTime=2017-04-01, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42e58111305, moduleTitle=2016NICE技术评估指南：Elbasvir–grazoprevir用于治疗慢性丙型肝炎（TA413）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42e58111305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714738, encodeId=6a461e1473853, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA授予礼来/阿斯利康阿尔茨海默氏症药物口服BACE抑制剂AZD3293快车道地位, objectType=article, longId=75773, objectId=b12ae57730c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12ae57730c, replyNumber=0, likeNumber=88, createdTime=2017-04-11, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12ae57730c, moduleTitle=FDA授予礼来/阿斯利康阿尔茨海默氏症药物口服BACE抑制剂AZD3293快车道地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12ae57730c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714742, encodeId=648c1e147420d, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, objectType=article, longId=93392, objectId=9692933925e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9692933925e, replyNumber=0, likeNumber=72, createdTime=2017-06-10, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9692933925e, moduleTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9692933925e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714739, encodeId=a7e21e14739ee, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet Respir Med：CXCR2拮抗剂AZD5069对难治性哮喘没什么作用, objectType=article, longId=77274, objectId=c12ee727447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c12ee727447, replyNumber=0, likeNumber=60, createdTime=2017-06-04, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c12ee727447, moduleTitle=Lancet Respir Med：CXCR2拮抗剂AZD5069对难治性哮喘没什么作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c12ee727447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714736, encodeId=95e11e14736a8, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=NEJM：达那唑（danazol）能逆转细胞衰老？, objectType=article, longId=73940, objectId=3637e394078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3637e394078, replyNumber=0, likeNumber=67, createdTime=2016-07-31, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3637e394078, moduleTitle=NEJM：达那唑（danazol）能逆转细胞衰老？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3637e394078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714731, encodeId=e5e61e14731e8, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）, objectType=article, longId=67240, objectId=9d3e6e240f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d3e6e240f2, replyNumber=0, likeNumber=62, createdTime=2016-05-12, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d3e6e240f2, moduleTitle=NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d3e6e240f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714737, encodeId=a35e1e1473757, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AIM：接受阿片类药物激动剂治疗的HCV患者使用elbasvir-grazoprevir治疗的SVR12较高, objectType=article, longId=74873, objectId=3233e487368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3233e487368, replyNumber=0, likeNumber=54, createdTime=2016-11-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3233e487368, moduleTitle=AIM：接受阿片类药物激动剂治疗的HCV患者使用elbasvir-grazoprevir治疗的SVR12较高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3233e487368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714733, encodeId=04e51e1473382, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题, objectType=article, longId=69344, objectId=8fa26934452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa26934452, replyNumber=0, likeNumber=71, createdTime=2016-10-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa26934452, moduleTitle=Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa26934452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714734, encodeId=daef1e147347c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=喜讯！欧盟批准阿斯利康新型抗生素Zavicefta（CAZ-AVI），治疗严重细菌性感染, objectType=article, longId=71848, objectId=ac88e1848fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac88e1848fb, replyNumber=0, likeNumber=56, createdTime=2016-07-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac88e1848fb, moduleTitle=喜讯！欧盟批准阿斯利康新型抗生素Zavicefta（CAZ-AVI），治疗严重细菌性感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac88e1848fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714728, encodeId=df6f1e1472838, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA批准Jazz制药罕见病药物Defitelio，用于肝静脉阻塞（VOD）, objectType=article, longId=65985, objectId=c98065985c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c98065985c3, replyNumber=0, likeNumber=59, createdTime=2017-01-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c98065985c3, moduleTitle=FDA批准Jazz制药罕见病药物Defitelio，用于肝静脉阻塞（VOD）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c98065985c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714735, encodeId=8b501e1473537, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=JAMA：Deutetrabenazine对亨廷顿病患者舞蹈病样症状的改善有效, objectType=article, longId=72169, objectId=e2eae21691e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2eae21691e, replyNumber=0, likeNumber=78, createdTime=2017-05-09, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2eae21691e, moduleTitle=JAMA：Deutetrabenazine对亨廷顿病患者舞蹈病样症状的改善有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2eae21691e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714729, encodeId=44891e14729e4, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Jazz制药肝脏罕见病药物Defitelio获FDA批准, objectType=article, longId=66092, objectId=125966092e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125966092e2, replyNumber=0, likeNumber=45, createdTime=2017-03-06, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125966092e2, moduleTitle=Jazz制药肝脏罕见病药物Defitelio获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125966092e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714722, encodeId=f5e81e14722ec, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=招募患者：AZD9291治疗局部晚期或转移性非小细胞肺癌的开放、单臂临床研究, objectType=article, longId=56013, objectId=e6a1560130a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6a1560130a, replyNumber=0, likeNumber=62, createdTime=2016-04-11, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6a1560130a, moduleTitle=招募患者：AZD9291治疗局部晚期或转移性非小细胞肺癌的开放、单臂临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6a1560130a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714725, encodeId=d0c91e1472563, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=ASH 2015：Gazyva联合苯丁酸氮芥一线治疗CLL后4年内无需治疗, objectType=article, longId=60416, objectId=efc1604161b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efc1604161b, replyNumber=0, likeNumber=48, createdTime=2016-09-02, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efc1604161b, moduleTitle=ASH 2015：Gazyva联合苯丁酸氮芥一线治疗CLL后4年内无需治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efc1604161b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714732, encodeId=4f021e14732c6, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA批准帕金森突破性药物Nuplazid上市许可, objectType=article, longId=67357, objectId=7a836e357ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a836e357ea, replyNumber=0, likeNumber=61, createdTime=2016-09-01, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a836e357ea, moduleTitle=FDA批准帕金森突破性药物Nuplazid上市许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a836e357ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Retina：内界膜剥离的眼睛和正常眼睛中较小的中央凹无血管区（FAZ）与较厚的中央凹相关！

2017-09-20

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

CLIN CANCER RES：AZD4547治疗晚期鳞状细胞肺癌患者

2018-04-07

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

罕见病重磅消息！全球脊髓性肌萎缩症（SMA）治疗药物Spinraza获美国FDA批准

2017-08-28

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究

2018-02-10

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet Infect Dis：Ridinilazole与万古霉素在治疗艰难梭菌感染的比较

2017-11-09

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

2016NICE技术评估指南：Elbasvir–grazoprevir用于治疗慢性丙型肝炎（TA413）发布

2017-04-01

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA授予礼来/阿斯利康阿尔茨海默氏症药物口服BACE抑制剂AZD3293快车道地位

2017-04-11

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批

2017-06-10

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet Respir Med：CXCR2拮抗剂AZD5069对难治性哮喘没什么作用

2017-06-04

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

NEJM：达那唑（danazol）能逆转细胞衰老？

2016-07-31

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）

2016-05-12

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AIM：接受阿片类药物激动剂治疗的HCV患者使用elbasvir-grazoprevir治疗的SVR12较高

2016-11-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题

2016-10-08

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

喜讯！欧盟批准阿斯利康新型抗生素Zavicefta（CAZ-AVI），治疗严重细菌性感染

2016-07-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA批准Jazz制药罕见病药物Defitelio，用于肝静脉阻塞（VOD）

2017-01-13

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

JAMA：Deutetrabenazine对亨廷顿病患者舞蹈病样症状的改善有效

2017-05-09

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Jazz制药肝脏罕见病药物Defitelio获FDA批准

2017-03-06

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

招募患者：AZD9291治疗局部晚期或转移性非小细胞肺癌的开放、单臂临床研究

2016-04-11

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

ASH 2015：Gazyva联合苯丁酸氮芥一线治疗CLL后4年内无需治疗

2016-09-02

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA批准帕金森突破性药物Nuplazid上市许可

2016-09-01

科室
- - 订阅+
  - 更多科室
工具
服务